

Research Compliance Activity and Turn-Around-Time (TAT) Summary Report

Fiscal Year 2023 (7/1/2022 to 6/30/2023)

TAT calculated from submission date to date of approval. TAT not calculated for continuing reviews.

| Institutional Biosafety Committee (IBC) - IUPUI | | | | | | | | |
|---|--------|--------|--------|--------|--------|--------|--------|--------|
| | Q1 TAT | | Q2 TAT | | Q3 TAT | | Q4 TAT | |
| | Mean | Median | Mean | Median | Mean | Median | Mean | Median |
| Full Board | | | | | | | | |
| New Studies - Full Board (to review) | 27.6 | 28.0 | | | | | | |
| New Studies - Full Board (to approval) | 49.4 | 48.5 | | | | | | |
| Exempt | | | | | | | | |
| New Studies - Exempt (to determination) | 14.25 | 14.0 | | | | | | |
| Amendments | | | | | | | | |
| Amendments - Minor | 5.5 | 2.0 | | | | | | |
| Amendments - Major | 15.0 | 13.0 | | | | | | |

| Area Activities/Throughput (T) | Q1 (Jul-Sep) | | | Q2 (Oct-Dec) | | | Q3 (Jan-Mar) | | | Q4 (Apr-Jun) | | |
|--------------------------------|--------------|------------|-----------------------------|--------------|-----------|-----------------------------|--------------|-----------|-----------------------------|--------------|-----------|-----------------------------|
| | Received | Completed | Throughput/ % Backlogged | Received | Completed | Throughput/ % Backlogged | Received | Completed | Throughput/ % Backlogged | Received | Completed | Throughput/ % Backlogged |
| New Studies - Full Board | 9 | 16 | 7 | | | n/a | | | n/a | | | n/a |
| New Studies - Exempt | 6 | 8 | 2 | | | n/a | | | n/a | | | n/a |
| Amendments - Minor | 115 | 124 | 9 | | | n/a | | | n/a | | | n/a |
| Amendments - Major | 19 | 24 | 5 | | | n/a | | | n/a | | | n/a |
| Continuing Reviews | 31 | 39 | 8 | | | n/a | | | n/a | | | n/a |
| TOTAL | 180 | 211 | 31 (-17.2%) | 0 | 0 | | 0 | 0 | | 0 | 0 | |

| Area Training Activities | Q1 (Jul-Sep) | Q2 (Oct-Dec) | Q3 (Jan-Mar) | Q4 (Apr-Jun) | FY TOTALS |
|-----------------------------|-----------------|-----------------|-----------------|-----------------|--------------|
| Presentations (# of events) | 0 | | | | 0 |

| Reportable Events/Activities | Q1 (Jul-Sep) | Q2 (Oct-Dec) | Q3 (Jan-Mar) | Q4 (Apr-Jun) | FY TOTALS |
|------------------------------|-----------------|-----------------|-----------------|-----------------|--------------|
| Immediate OBA Report | 0 | | | | 0 |
| 30 Day OBA Report | 0 | | | | 0 |
| Lab Accident/Injury/Exposure | 0 | | | | 0 |

Reporting Agency: NIH Office of Biotechnology Activities (OBA)

Research Compliance Activity and Turn-Around-Time (TAT) Summary Report
Fiscal Year 2023 (7/1/2022 to 6/30/2023)

| Institutional Biosafety Committee (IBC) - IU Indianapolis | | | | | | | | | | | | | | | | |
|---|-------------|---------------|----------------|------------------|-------------|---------------|----------------|------------------|-------------|---------------|----------------|------------------|-------------|---------------|----------------|------------------|
| | Q1 TAT | | | | Q2 TAT | | | | Q3 TAT | | | | Q4 TAT | | | |
| | Review Mean | Review Median | Total TAT Mean | Total TAT Median | Review Mean | Review Median | Total TAT Mean | Total TAT Median | Review Mean | Review Median | Total TAT Mean | Total TAT Median | Review Mean | Review Median | Total TAT Mean | Total TAT Median |
| Initial | | | | | | | | | | | | | | | | |
| Full Committee | | | | | 15 | 21 | 35 | 38 | 44 | 51 | 57 | 55 | | | | |
| Biosafety Officer Review | | | | | 22 | 16 | 40 | 38 | 24 | 24 | 26 | 26 | | | | |
| Amended | | | | | | | | | | | | | | | | |
| Full Committee | | | | | 29 | 27 | 31 | 31 | 36 | 29 | 42 | 33 | | | | |
| Biosafety Officer Review | | | | | 5 | 3 | 8 | 5 | 11 | 8 | 15 | 11 | | | | |
| Renewed/Amended | | | | | | | | | | | | | | | | |
| Full Committee | | | | | 38 | 39 | 42 | 44 | 40 | 39 | 51 | 47 | | | | |
| Biosafety Officer Review | | | | | 9 | 7 | 13 | 9 | 11 | 10 | 18 | 15 | | | | |
| Renewed | | | | | | | | | | | | | | | | |
| Full Committee | | | | | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Biosafety Officer Review | | | | | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | | | | |

| Area Activities/Throughput (T) | Q1 | | | Q2 | | | Q3 | | | Q4 | | |
|--|----------|-----------|------------|----------|-----------|------------|----------|-----------|------------|----------|-----------|------------|
| | Received | Completed | Throughput | Received | Completed | Throughput | Received | Completed | Throughput | Received | Completed | Throughput |
| Initial Full Committee | | | | 8 | 4 | -4 | 8 | 1 | -7 | | | 0 |
| Initial Biosafety Officer Review | | | | 9 | 9 | 0 | 3 | 2 | -1 | | | 0 |
| Amended Full Committee | | | | 10 | 7 | -3 | 11 | 7 | -4 | | | 0 |
| Amended Biosafety Officer Review | | | | 65 | 49 | -16 | 84 | 76 | -8 | | | 0 |
| Renewed/Amended Full Committee | | | | 23 | 12 | -11 | 17 | 9 | -8 | | | 0 |
| Renewed/Amended Biosafety Officer Review | | | | 113 | 92 | -21 | 85 | 70 | -15 | | | 0 |
| Renewed Full Committee | | | | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Renewed Biosafety Officer Review | | | | 5 | 4 | -1 | 3 | 2 | -1 | | | 0 |
| TOTAL | | | | 233 | 177 | -56 | 211 | 167 | -44 | 0 | 0 | 0 |

| Reportable Events/Activities | Q1 | Q2 | Q3 | Q4 | FY TOTALS |
|------------------------------|----|----|----|----|-----------|
| Immediate OBA Report | 0 | 0 | 0 | | 0 |
| 30 Day OBA Report | 0 | 0 | 0 | | 0 |
| Lab Accident/Injury/Exposure | 0 | 0 | 1 | | 1 |

| Area Training Activities (all campuses) | Q1 | Q2 | Q3 | Q4 | FY TOTALS |
|---|----|----|----|----|-----------|
| Presentations (# of events) | 0 | 1 | 0 | | 1 |

Reporting Agency: NIH Office of Biotechnology Activities (OBA)
FY2023 Q1 metrics are from a legacy system.